Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXVIII/226: 191-195 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXVIII/226: 191-195

Title: Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments

Authors: Kukla U, Łabuzek K, Chronowska J, Bobrzyk M, Madej P, Okopień B. 

More details

01/226

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments


Kukla U1, Łabuzek K1, Chronowska J1, Bobrzyk M1, Madej P2, Okopień B1.

Medical University of Silesia, Katowice, Poland: 1Department of Internal Medicine and Clinical Pharmacology; 2Department of Endocrinological Gynecology

Pheochromocytoma is a very rare tumor that stems from chromaffin cells and usually develops in the adrenal glands. Its equivalent, which exists outside of the adrenal glands, is paraganglioma. Approximately 10-26% of pheochromocytoma is malignant, what poses a significant therapeutical problem, as its presence, together with an abundant production of catecholamines, may lead to a number of perilous complications, such as spinal cord oppression or the damage of organs, what is responsible for producing catecholamines. Due to the risk that the tumor is, it is essential to invent new and effective ways of treatment. In case of malignant tumors stemming from chromaffin cells, much is expected from antiangiogenic medicine. Its functioning consists of stopping of the process of neovascularization, which is indispensable for the development of the tumor. Sunitinib – a tyrosine kinase inhibitor – is perhaps the most promising antiangiogenic medicine, whose effectiveness is currently being evaluated in 2nd phase clinical trials. Attemps are also being made to conduct treatment with the use of other medicine of similar functioning, such as: thalidomide, imatinib or evrolimus.

Key words: angiogenesis, antiangiogenic therapy, sunitinib, pheochromocytoma, paraganglioma

Pol Med J, 2015; XXXVIII (226); 191–195